Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

NCT05016661 is registered in ClinicalTrials.gov with AEON Biopharma, Inc. as lead sponsor.

NCT NCT05016661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05016661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Lead sponsor
AEON Biopharma, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 19, 2021
Completion date
August 30, 2024
Enrollment
466 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

migraine